PATENT CLAIM ANALYSIS

Application Number: 15882662
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2019-01
Patent Classification: ["424", "200100"]

Abstract:
Provided herein are prime-boost regimens and materials used therein. The prime-boost regimens enhance the immune response to a target antigen. The vaccines used for boost are comprised of recombinant attenuated metabolically active  Listeria  that encodes an expressible antigen that is cross-reactive with the target antigen. In some examples, the immune response is a cellular immune response.

Claim (Index 58):
A method according to  claim 52 , wherein the cancer antigen is selected from the group consisting of mesothelin, PSMA, PAP, SSX-2, NY-ESO-1, RASG12D, RASG12V, and RASG13D.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 86.0
- Lexical Diversity: 1.4878
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13699687', '12374288', '14589608', '14952281', '11021441']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8424777242092935
- 35 USC 102 Novelty (BERT): 0.5789685848225836
- Combined Prediction Score: 0.8161268102706225
- Mean Citation Score: 563.6098939999998
- Max Citation Score: 627.5378400000002
- Similarity Product: 382.0440607132388

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test